Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Chromadex Corp CS (NQ: CDXC ) 3.070 -0.120 (-3.76%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Chromadex Corp CS < Previous 1 2 3 4 Next > Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College August 15, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Corporation Reports Second Quarter 2022 Financial Results August 10, 2022 From ChromaDex Corporation Via Business Wire ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022 August 02, 2022 From ChromaDex Corporation Via Business Wire ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR) July 07, 2022 From ChromaDex Corporation Via Business Wire ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB) June 15, 2022 From ChromaDex Corporation Via Business Wire ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference June 07, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China June 10, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea June 02, 2022 From ChromaDex Corporation Via Business Wire ChromaDex to Present at the LD Micro Invitational June 01, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China May 19, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen® May 17, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Corporation Reports First Quarter 2022 Financial Results May 12, 2022 From ChromaDex Corporation Via Business Wire ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022 April 29, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors April 22, 2022 From ChromaDex Corporation Via Business Wire ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World April 14, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio April 06, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations March 16, 2022 From ChromaDex Corporation Via Business Wire ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022 February 22, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside February 09, 2022 From ChromaDex Corporation Via Business Wire ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients January 31, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation January 25, 2022 From ChromaDex Corporation Via Business Wire ChromaDex and Designs for Health Partner for New Product Development on Niagen® January 20, 2022 From ChromaDex Corporation Via Business Wire ChromaDex Corporation Reports Third Quarter 2021 Financial Results November 03, 2021 From ChromaDex Corporation Via Business Wire ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT) October 18, 2021 From ChromaDex Corporation Via Business Wire ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021 October 13, 2021 From ChromaDex Corporation Via Business Wire ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth October 01, 2021 From ChromaDex Corporation Via Business Wire ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China September 29, 2021 From ChromaDex Corporation Via Business Wire ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™) September 20, 2021 From ChromaDex Corporation. Via Business Wire ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit September 15, 2021 From ChromaDex Corporation Via Business Wire ChromaDex Corporation Reports Second Quarter 2021 Financial Results August 03, 2021 From ChromaDex Corporation Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.